Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 September 2019

Abstract and Keywords

Mental illness is the primary risk factor for suicidal ideation, attempts, and completion. Effective treatment of the psychiatric condition is the foundational strategy to reduce the risk of suicide associated with these conditions, but few medications can be demonstrated to independently reduce the risk of suicide. This chapter will describe how psychopharmacological treatment can be included as a component of bio-psycho-social treatments within the context of a recovery model for suicide prevention. The evidence for medication therapies will be reviewed both for specific behavioral health conditions and for any reduced suicide risk independent of general therapeutic effects to treat underlying conditions. A framework strategy will be described for the integration of evidence-based clinical decision making to provide the most effective treatment that also specifically targets suicide risk for patients.

Keywords: suicide, psychopharmacotherapy, antidepressants, mood stabilizers, antipsychotics, lithium, clozapine, ketamine

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.